Lv715
5000 积分 2024-05-28 加入
Loss of JAK1 Function Causes G2/M Cell Cycle Defects Vulnerable to KIF18A Inhibition
9天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
13天前
已完结
Alpelisib-induced severe interstitial lung disease: case report
1个月前
已关闭
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
2个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
3个月前
已完结
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents
3个月前
已关闭
A patent review of BRD4 inhibitors (2013-2019)
3个月前
已完结
BET inhibitors: an updated patent review (2018–2021)
3个月前
已完结
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
3个月前
已完结
A patent review of BRD4 inhibitors (2020-present)
3个月前
已完结
皖公网安备34019202002308
